Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Senexis to develop novel treatments for ageing-related diseases

BTG : 07 October, 2006  (Company News)
BTG plc, the global technology commercialisation company, today announced an investment in Senexis Limited, a new biotechnology company focusing on the development of pharmaceuticals for the diagnosis and treatment of ageing-related diseases caused by a common pathogenic process called amyloidosis. Senexis Limited has raised
Senexis Limited was founded by Kelvin Stott (formerly of Cambridge University and McKinsey) and Andrew Doig (a Senior Lecturer in the Department of Biomolecular Sciences at UMIST), who together discovered a novel class of potent inhibitors that can effectively block and reverse the key step in this process of protein/peptide aggregation. Amyloidosis is now believed to be fundamental to the pathology of at least 20 currently incurable ageing-related diseases, including type II diabetes, Alzheimer’s and Parkinson’s diseases, as well as Huntington’s disease, CJD/BSE and Motor Neurone Disease.

Commenting on the deal, Anthony Lando, Chief Operating Officer of BTG, said: “BTG has worked closely with Senexis’ founders over the past six months. We are committed to providing ongoing support to help the company realise the full potential of its exciting technology for the diagnosis and treatment of ageing-related diseases.”

Kelvin Stott, Senexis’ Chief Scientific Officer, commented: “We are thrilled to have secured funding from BTG and Catalyst Biomedica. Amyloid-related diseases affect over 50 million people in the developed world, costing approximately $500 billion a year. I am confident that our technology has the potential to revolutionise the diagnosis and treatment of these diseases.”

Andrew Doig, Research Director at Senexis, added: “Our initial results look very promising. Our lead compounds appear to inhibit and reverse the pathogenic process associated with these diseases very effectively.”

Senexis’ operations will be based at UMIST, where the university’s Technology transfer company, UMIST Ventures Limited, was closely involved in forming the company. Paul McCubbin of BTG will join the Board of Senexis and Mark Treherne (formerly of Pfizer, Cambridge Drug Discovery and BioFocus) will be Chief Executive Officer. Sharon Spencer of Catalyst BioMedica will act as observer on the Board.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo